Tafasitamab plus lenalidomide versus standard of care as second‐line (2L) therapy for patients with R/R DLBCL: A post hoc internal 2L analysis of L‐MIND (IN 2L‐MIND) Meeting Abstract
| Authors: | Sehn, L. H.; Kuruvilla, J.; Salles, G.; Maddocks, K. J.; Koch, C.; Xue, Z.; Amoloja, T.; Amin, A.; Duell, J. |
| Abstract Title: | Tafasitamab plus lenalidomide versus standard of care as second‐line (2L) therapy for patients with R/R DLBCL: A post hoc internal 2L analysis of L‐MIND (IN 2L‐MIND) |
| Meeting Title: | 17th International Conference on Malignant Lymphoma (ICML) |
| Journal Title: | Hematological Oncology |
| Volume: | 41 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2023 Jun 13-17 |
| Meeting Location: | Lugano, Switzerland |
| ISSN: | 0278-0232 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2023-06-01 |
| Start Page: | 441 |
| End Page: | 442 |
| Language: | English |
| DOI: | 10.1002/hon.3164_325 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: 325 -- Source: Cinahl |
